Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
- PMID: 22868819
- DOI: 10.1001/archinternmed.2012.3147
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
Abstract
BACKGROUND Treatment of hypertension in patients with diabetes mellitus (DM) has been shown to improve cardiovascular outcomes; however, the value of intensive blood pressure (BP) targets remains uncertain. We sought to determine the effectiveness and safety of treating BP to intensive targets (upper limit of 130 mm Hg systolic and 80 mm Hg diastolic) compared with standard targets (upper limit of 140-160 mm Hg systolic and 85-100 mm Hg diastolic) in patients with type 2 DM. METHODS Using electronic databases, bibliographies, and clinical trial registries, we conducted a systematic review and meta-analysis to identify randomized trials enrolling adults diagnosed as having type 2 DM and comparing prespecified BP targets. Data on study characteristics, risk for bias, and outcomes were collected. Random-effects models were used to pool relative risks and risk differences for mortality, myocardial infarction, and stroke. RESULTS The use of intensive BP targets was not associated with a significant decrease in the risk for mortality (relative risk difference, 0.76; 95% CI, 0.55-1.05) or myocardial infarction (relative risk difference, 0.93; 95% CI, 0.80-1.08) but was associated with a decrease in the risk for stroke (relative risk, 0.65; 95% CI, 0.48-0.86). The pooled analysis of risk differences associated with the use of intensive BP targets demonstrated a small absolute decrease in the risk for stroke (absolute risk difference, -0.01; 95% CI, -0.02 to -0.00) but no statistically significant difference in the risk for mortality or myocardial infarction. CONCLUSION Although the use of intensive compared with standard BP targets in patients with type 2 DM is associated with a small reduction in the risk for stroke, evidence does not show that intensive targets reduce the risk for mortality or myocardial infarction.
Comment in
-
Diabetes: no clear advantage for intensive blood pressure control in T2DM.Nat Rev Endocrinol. 2012 Nov;8(11):628. doi: 10.1038/nrendo.2012.158. Epub 2012 Aug 28. Nat Rev Endocrinol. 2012. PMID: 22926100 No abstract available.
-
ACP Journal Club. Review: Intensive blood pressure control reduces stroke, but not mortality or MI, in type 2 diabetes.Ann Intern Med. 2013 Jan 15;158(2):JC5. doi: 10.7326/0003-4819-158-2-201301150-02005. Ann Intern Med. 2013. PMID: 23318339 No abstract available.
-
Meta-analysis shows limited benefit of lowering blood pressure below 130/80 mm Hg in patients with type 2 diabetes.Evid Based Med. 2013 Dec;18(6):222-3. doi: 10.1136/eb-2013-101302. Epub 2013 May 3. Evid Based Med. 2013. PMID: 23645888 No abstract available.
Similar articles
-
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials.Circulation. 2011 Jun 21;123(24):2799-810, 9 p following 810. doi: 10.1161/CIRCULATIONAHA.110.016337. Epub 2011 May 31. Circulation. 2011. PMID: 21632497
-
Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials.Heart. 2013 May;99(9):601-13. doi: 10.1136/heartjnl-2012-301968. Epub 2012 Aug 21. Heart. 2013. PMID: 22914531 Review.
-
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients.J Hypertens. 2011 Jul;29(7):1253-69. doi: 10.1097/HJH.0b013e3283469976. J Hypertens. 2011. PMID: 21505352
-
Evidence based evaluation of immuno-coagulatory interventions in critical care.Dan Med Bull. 2011 Sep;58(9):B4316. Dan Med Bull. 2011. PMID: 21893014 Review.
-
Systolic blood pressure and cardiovascular outcomes during treatment of hypertension.Am J Med. 2013 Jun;126(6):501-8. doi: 10.1016/j.amjmed.2013.01.007. Epub 2013 Mar 28. Am J Med. 2013. PMID: 23541376 Clinical Trial.
Cited by
-
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.J Atheroscler Thromb. 2024 Jun 1;31(6):641-853. doi: 10.5551/jat.GL2022. Epub 2023 Dec 19. J Atheroscler Thromb. 2024. PMID: 38123343 Free PMC article. No abstract available.
-
Rationale and design for the Blood Pressure Control Target in Diabetes (BPROAD) study.J Diabetes. 2023 Dec;15(12):1029-1040. doi: 10.1111/1753-0407.13411. Epub 2023 Jun 21. J Diabetes. 2023. PMID: 37345251 Free PMC article. Clinical Trial.
-
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010315. doi: 10.1002/14651858.CD010315.pub5. Cochrane Database Syst Rev. 2022. PMID: 36398903 Free PMC article. Review.
-
Internal Medicine Resident Adherence to Evidence-Based Practices in Management of Diabetes Mellitus.J Med Educ Curric Dev. 2022 Feb 2;9:23821205221076659. doi: 10.1177/23821205221076659. eCollection 2022 Jan-Dec. J Med Educ Curric Dev. 2022. PMID: 35128060 Free PMC article.
-
Deep Neural Network for Reducing the Screening Workload in Systematic Reviews for Clinical Guidelines: Algorithm Validation Study.J Med Internet Res. 2020 Dec 30;22(12):e22422. doi: 10.2196/22422. J Med Internet Res. 2020. PMID: 33262102 Free PMC article.
LinkOut - more resources
Full Text Sources
